Equities

Alliance Pharma PLC

APH:LSE

Alliance Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)34.95
  • Today's Change0.05 / 0.14%
  • Shares traded330.99k
  • 1 Year change-41.56%
  • Beta0.8320
Data delayed at least 20 minutes, as of Apr 26 2024 17:46 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy3
Outperform2
Hold2
Underperform0
Sell0

Share price forecast

The 7 analysts offering 12 month price targets for Alliance Pharma plc have a median target of 60.00, with a high estimate of 100.00 and a low estimate of 42.00. The median estimate represents a 71.67% increase from the last price of 34.95.
High186.1%100.00
Med71.7%60.00
Low20.2%42.00

Dividends

In 2022, Alliance Pharma PLC reported a dividend of 0.02 GBP, which represents a 5.03% increase over last year. The 4 analysts covering the company expect dividends of 0.01 GBP for the upcoming fiscal year, a decrease of 38.06%.
Div growth (TTM)5.03%
More ▼

Earnings history & estimates

Alliance Pharma plc reported annual 2022 earnings of 4.23 per share on Mar 21, 2023.
Average growth rate+1.40%
More ▼

Revenue history & estimates

Alliance Pharma plc had revenues for the full year 2022 of 167.42m. This was 2.58% above the prior year's results.
Average growth rate+9.69%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.